Tardive dyskinesia in bipolar affective disorder: a catchment area study.

abstract：:The objective of this study was to examine the safety and tolerability of duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, in a large cohort of elderly patients with major depressive disorder. Data were pooled from 8-week and 12-week, double-blind, randomized, placebo-controlled trials of dulox...

journal_title：International clinical psychopharmacology

authors： Oakes TM,Katona C,Liu P,Robinson M,Raskin J,Greist JH

更新日期：2013-01-01 00:00:00

abstract：:The tricyclic antidepressants (TCAs) are still considered as first-line treatment for depression, despite the availability of the selective serotonin reuptake inhibitors (SSRIs). This paper considers the current situation in reverse by assuming that only the SSRIs, in particular fluvoxamine, are available and the TCAs...

journal_title：International clinical psychopharmacology

authors： Ashford JJ

更新日期：1995-01-01 00:00:00

abstract：:An assessment of the efficacy of treatments in panic disorder and agoraphobia (PDA) is complicated by methodological problems resulting from the complexity of these disorders. In this paper, commonly used anxiety scales are discussed with regard to their relevance in the assessment of PDA. Although there are already m...

journal_title：International clinical psychopharmacology

authors： Bandelow B,Hajak G,Holzrichter S,Kunert HJ,Rüther E

更新日期：1995-06-01 00:00:00

abstract：:Recent meta-analytic work suggests atypical antipsychotics may be clinically superior to conventional antipsychotics, although many stable patients remain on conventional antipsychotic treatment. A long-acting atypical agent may benefit patients in realms of both advanced medication delivery and mechanism of action. I...

journal_title：International clinical psychopharmacology

authors： van Os J,Bossie CA,Lasser RA

更新日期：2004-07-01 00:00:00

abstract：:This study evaluated the efficacy of pregabalin augmentation of antidepressant treatment in patients with posttraumatic stress disorder (PTSD). Nine patients meeting Diagnostic and Statistical Manual, fourth edition criteria for PTSD who were on stable doses of antidepressants were treated open label with flexibly dos...

journal_title：International clinical psychopharmacology

authors： Pae CU,Marks DM,Han C,Masand PS,Patkar AA

更新日期：2009-01-01 00:00:00

abstract：:Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no sign...

journal_title：International clinical psychopharmacology

authors： Berk M,Ichim L,Brook S

更新日期：1999-11-01 00:00:00

abstract：:Musical hallucinations (MHs), characterized by the hearing of tunes, melodies, or songs, is a relatively under-recognized phenomenon among elderly individuals with hearing impairment. In some patients, MHs represent a complex psychopathological phenomenon, hallucinatory in content and obsessive-compulsive (OC) in form...

journal_title：International clinical psychopharmacology

authors： Bergman J,Pashinian A,Weizman A,Poyurovsky M

更新日期：2014-09-01 00:00:00

abstract：:In a double-blind, between-patient clinical trial carbamazepine (CBZ) (n = 8) was compared to haloperidol (HP) (n = 9) in patients presenting with mania (DSM III). Seven patients on HP and 2 on CBZ failed to complete 4 weeks treatment. In 4 of the HP group this was because of extrapyramidal side-effects (EPS). Two pat...

journal_title：International clinical psychopharmacology

authors： Brown D,Silverstone T,Cookson J

更新日期：1989-07-01 00:00:00

abstract：:Data from the National Comorbidity Survey (NCS) general population study and the World Health Organization (WHO) primary care study have established that comorbidity between panic and depression is one of the strongest psychiatric associations. The two studies agree that patients with panic-depression comorbidity have...

journal_title：International clinical psychopharmacology

authors： Ballenger JC

更新日期：1998-04-01 00:00:00

abstract：:The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Import...

journal_title：International clinical psychopharmacology

authors： Silver H

更新日期：2003-11-01 00:00:00

abstract：:Major depressive disorder (MDD) is currently the second most common cause of disability worldwide. Current treatment of MDD with selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors is limited by efficacy and tolerability issues, highlighting the unmet need in the treatment of patien...

journal_title：International clinical psychopharmacology

authors： Montgomery SA

更新日期：2008-03-01 00:00:00

abstract：:In a total population of patients with a schizophrenic syndrome, the amount of antipsychotic drugs during a defined period was studied. Doses of antipsychotics were higher in males than in females, low to moderate in most patients, and decreased with the duration of illness. There was a significant negative correlatio...

journal_title：International clinical psychopharmacology

authors： Lindström E,Widerlöv B,von Knorring L

更新日期：1996-12-01 00:00:00

abstract：:On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder. Evaluating the efficacy of 5-hydroxytrypt...

journal_title：International clinical psychopharmacology

authors： Yousefzadeh F,Sahebolzamani E,Sadri A,Mortezaei A,Aqamolaei A,Mortazavi SH,Shalbafan MR,Ghaffari S,Alikhani R,Mousavi SB,Naderi S,Shamabadi A,Jalilevand S,Akhondzadeh S

更新日期：2020-09-01 00:00:00

abstract：:Duloxetine, an inhibitor of serotonin and norepinephrine reuptake, has been approved for the treatment of major depressive disorder. In this analysis, data from eight, double-blind, placebo-controlled duloxetine trials were pooled, and the response to duloxetine treatment (40-120 mg/day) was compared between patients ...

journal_title：International clinical psychopharmacology

authors： Perahia DG,Kajdasz DK,Royer MG,Walker DJ,Raskin J

更新日期：2006-09-01 00:00:00

abstract：:Post-traumatic stress disorder (PTSD) is frequently treated with antidepressant medications, especially the newer selective serotonergic antidepressants which have documented efficacy in PTSD. Analogous to depression, however, some PTSD patients may not have a satisfactory response to these agents. This case report de...

journal_title：International clinical psychopharmacology

authors： Hamner MB,Frueh BC

更新日期：1998-09-01 00:00:00

abstract：:The objective of this study was to evaluate the effectiveness and tolerability of aripiprazole use in child and adolescent psychiatric inpatients. This was a naturalistic, retrospective evaluation of the discharged patients treated with aripiprazole on the child and adolescent unit at the Austin State Hospital. To be ...

journal_title：International clinical psychopharmacology

authors： Gibson AP,Crismon ML,Mican LM,Fischer C

更新日期：2007-03-01 00:00:00

abstract：:We report that perospirone may have had positive effects on the obesity of three patients with schizophrenia and on the fasting blood sugar (FBS) and HbA1C of two of them who had type 2 diabetes mellitus. ...

journal_title：International clinical psychopharmacology

authors： Nishida M,Nakamura M

更新日期：2004-01-01 00:00:00

abstract：:Thirty healthy subjects 12 males and 18 females were given the acetylcholinesterase inhibitor pyridostigmine (120 mg) orally. The growth hormone (GH) response was measured as the maximum GH level post-pyridostigmine relative to baseline. Twenty-six subjects increased their GH level in response to pyridostigmine. Respo...

journal_title：International clinical psychopharmacology

authors： Lucey JV,O'Keane V,O'Flynn K,Clare AW,Dinan TG

更新日期：1991-07-01 00:00:00

abstract：:It has been suggested that dopamine/serotonin (5-HT) imbalance, with relative enhancement of serotonergic activity, might be one of the possible pathophysiological mechanisms underlying neuroleptic-induced akathisia. On the basis of preclinical data, which imply that the partial 5-HT1A agonist buspirone possesses anti...

journal_title：International clinical psychopharmacology

authors： Poyurovsky M,Weizman A

更新日期：1997-09-01 00:00:00

abstract：:Although life prevalence of substance use disorders among patients with schizophrenia is close to 50%, few studies have been carried out to date to identify an integrated pharmacological treatment for this comorbidity. So far, the most promising results, that we report here, have been obtained with clozapine. To a les...

journal_title：International clinical psychopharmacology

authors： Potvin S,Stip E,Roy JY

更新日期：2003-05-01 00:00:00

abstract：:The negative symptoms of schizophrenia remain a major clinical challenge. Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor. This study was a 6-week randomized placebo-controlled trial of reboxetine or placebo add on to haloperidol 5 mg in the treatment of 30 pati...

journal_title：International clinical psychopharmacology

authors： Schutz G,Berk M

更新日期：2001-09-01 00:00:00

abstract：:Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-week, randomized, dou...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Mansuy L,Ruth AC,Li D,Gommoll C

更新日期：2014-01-01 00:00:00

abstract：:Studies on humans show that depressive disorder is associated with an increased risk of developing cognitive dysfunction, and animal studies suggest that antidepressants may have neuroprotective abilities. On the basis of these observations, it was hypothesized that treatment with antidepressants may decrease the risk...

journal_title：International clinical psychopharmacology

authors： Kessing LV,Forman JL,Andersen PK

更新日期：2011-11-01 00:00:00

abstract：:Treatments given to patients with primary psychotic disorders include mood stabilizers (MSs) combined with other psychotropics, despite the limited evidence of efficacy, safety, and lack of regulatory approval. We analyzed records of 636 inpatients at the McLean Hospital (2002-2009), who were diagnosed with bipolar di...

journal_title：International clinical psychopharmacology

authors： Ventriglio A,Vincenti A,Centorrino F,Talamo A,Fitzmaurice G,Baldessarini RJ

更新日期：2011-03-01 00:00:00

abstract：:The present study aimed to compare health outcomes and tolerability according to antipsychotic medication (olanzapine, risperidone or an oral typical antipsychotic) after 6 months of treatment in a group of 919 schizophrenic patients who had never previously been treated with antipsychotics. Demographic and clinical p...

journal_title：International clinical psychopharmacology

authors： Gasquet I,Haro JM,Novick D,Edgell ET,Kennedy L,Lepine JP,SOHO Study Group.

更新日期：2005-07-01 00:00:00

abstract：:While the incidence and psychiatric correlates of violent trauma among children and adolescents have been well documented, there is less data on the specific ways in which girls are affected by violence. The present review examines current knowledge of the prevalence and effects of violent trauma on female children an...

journal_title：International clinical psychopharmacology

authors： Kaminer D,Seedat S,Lockhat R,Stein DJ

更新日期：2000-11-01 00:00:00

abstract：:In a double-blind multi-centre study of general practice patients with DSM-III-R major depressive disorder, sertraline (50 or 100 mg/day) was compared with dothiepin (75 or 150 mg/day) and with placebo. There were 83, 96 and 90 patients evaluated in the respective treatment groups; treatment lasted 6 weeks. Patients w...

journal_title：International clinical psychopharmacology

authors： Doogan DP,Langdon CJ

更新日期：1994-07-01 00:00:00

abstract：:Scientific, professional, and governmental bodies have in recent years intensified efforts to formulate guidelines for the treatment of depression with the goal that medical practice should comply with these standards and thus improve patient care. 'Evidence-based medicine' demands that medical practice should explici...

journal_title：International clinical psychopharmacology

authors： Linden M

更新日期：1999-06-01 00:00:00

abstract：:This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...

journal_title：International clinical psychopharmacology

authors： Docherty JP,Bossie CA,Lachaux B,Bouhours P,Zhu Y,Lasser R,Gharabawi GM

更新日期：2007-01-01 00:00:00

abstract：:A new short-acting thieno-diazepine compound, brotizolam, has been compared to nitrazepam in a double-blind trial. Following an initial 3-day control period with no treatment, insomniac patients were allocated to 2 weeks treatment with one or the other drug according to random selection. This was then followed by a fu...

journal_title：International clinical psychopharmacology

authors： Wheatley D

更新日期：1986-01-01 00:00:00